Figure 1

Effect of the SCD1 inhibitor Cay10566, Ze 117, dexamethasone and combinations of Cay10566/dexamethasone and Ze 117/dexamethasone on a variety of parameters. Relative fold change of SCD1 (A) and SCD2 (B) mRNA levels in C6 cells pretreated with dexamethasone, Ze 117, and their combination for 48 h compared to untreated control (UTC) cells. Relative mRNA fold changes were calculated by using a modified version of the Pfaffl equation with actin beta (Actb), ribosomal protein L21 (RPL21) and ribosomal protein L13 (Rpl13) as reference genes. Relative fold change in DPH fluorescence anisotropy measured in the plasma membrane of C6 cells in suspension after a 48 h preincubation with (C) different concentrations of the SCD inhibitor CAY10566 compared to untreated control cells (UTC) and (D) either dexamethasone (1.0 µM) alone or in combination with Ze 117 (25.0 µg/ml) or CAY10556 (1.0 µM). The effect of dexamethasone and Ze 117 as a single treatment and in combination on the ratio of (E) palmitate (C16:0) and palmitoleate (C16:1) as well as of (F) stearate (C18:0) and oleate (C18:1) after 48 h of treatment compared to the effect of the SCD inhibitor Cay10566. The relative fatty acid abundance values of each test condition were set into a ratio and normalized to the mean ratio of the respective untreated control (UTC). All results shown in this figure are displayed as the mean and SEM of at least three individual experiments. Values marked * were considered significantly different (unpaired t test with Welch’s correction) compared to the untreated control with p ≤ 0.05.